Genetic Studies of Actinic Keratosis Development: Where Are We Now?

被引:2
|
作者
Lee, Young Bok [1 ,2 ,3 ]
Kim, Jong-Il [3 ,4 ,5 ,6 ,7 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, Seoul, South Korea
[2] Catholic Univ Korea, Coll Med, Dept Dermatol, Seoul, South Korea
[3] Seoul Natl Univ, Genom Med Inst GMI, Med Res Ctr, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea
[5] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea
[7] Seoul Natl Univ, Coll Med, Dept Biomed Sci, 103 Daehak Ro, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Actinic keratosis; Cutaneous squamous cell carcinoma; SQUAMOUS-CELL CARCINOMA; CHROMOSOMAL-ABERRATIONS; SKIN; MUTATIONS; CANCER; P53; P16(INK4A); EXPRESSION; PATTERNS; RISK;
D O I
10.5021/ad.23.072
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Actinic keratosis (AK) is a common precancerous skin lesion that can develop into cutaneous squamous cell carcinoma (CSCC). AK is characterized by atypical keratinocytes in the skin's outer layer and is commonly found in sun-exposed areas. Like many precancerous lesions, the development of AK is closely associated with genetic mutations. The molecular biology and transcriptional mechanisms underlying AK development are not well understood. Ultraviolet (UV) light exposure, especially UVA and UVB radiation, is a significant risk factor for AK, causing DNA damage and mutagenic effects. Besides UV exposure, comorbidities like diabetes, rheumatoid arthritis, and psoriasis may also influence AK development. AK patients have shown associations with various internal malignancies, indicating potential vulnerability in cancer-associated genes. Treatment for AK includes cryosurgery, electrodesiccation and curettage, chemotherapeutic creams, photodynamic therapy, or topical immune-modulators. Genomic studies have identified genetic aberrations in AK, with common mutations found in genes like TP53, NOTCH1, and NOTCH2. The progression from AK to CSCC involves chromosomal aberrations and alterations in oncogenes and tumor-suppressor genes. The functional relationships among these genes are not fully understood, but network analysis provides insights into their potential mechanisms. Further research is needed to enhance our understanding of AK's pathogenesis and develop novel therapeutic approaches.
引用
收藏
页码:389 / 399
页数:11
相关论文
共 50 条
  • [41] Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
    Nicola Fazio
    Omar Abdel-Rahman
    Current Treatment Options in Oncology, 2021, 22
  • [42] Laboratory medicine and sports: where are we now?
    Derek, Lovorka
    Biljak, Vanja Radisic
    Marevic, Sanja
    Simac, Brankica
    Zarak, Marko
    Perovic, Antonija
    Marijancevic, Domagoj
    Buljubasic, Robert
    Matanovic, Luka
    Berkovic, Maja Cigrovski
    BIOCHEMIA MEDICA, 2024, 34 (03)
  • [43] Osteoporosis in Africa-where are we now
    Paruk, F.
    Tsabasvi, M.
    Kalla, A. A.
    CLINICAL RHEUMATOLOGY, 2021, 40 (09) : 3419 - 3428
  • [44] Fighting for Academic Surgical Oncology: Where Do We Come From, Where Are We Now, and Where Should We Head?
    Izbicki, Jakob R.
    ANNALS OF SURGERY, 2015, 262 (05) : 701 - 703
  • [45] Mobile Phones, Brain Tumors, and the Interphone Study: Where Are We Now?
    Swerdlow, Anthony J.
    Feychting, Maria
    Green, Adele C.
    Kheifets, Leeka
    Savitz, David A.
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2011, 119 (11) : 1534 - 1538
  • [46] Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies?
    Nassief, George
    Anaeme, Angela
    Moussa, Karen
    Chen, David
    Ansstas, George
    PHARMACEUTICALS, 2024, 17 (07)
  • [47] Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here?
    Lippi, Giuseppe
    Plebani, Mario
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (12) : 2075 - 2080
  • [48] CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh, Arnab
    Mailankody, Sham
    Giralt, Sergio A.
    Landgren, C. Ola
    Smith, Eric L.
    Brentjens, Renier J.
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2056 - 2067
  • [49] Advanced endoscopic therapeutics in Barrett's neoplasia: where are we now and where are we heading?
    Longcroft-Wheaton, Gaius
    Bhandari, Pradeep
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (05) : 543 - 545
  • [50] Joint ESC/EASD Guidelines on Diabetes, where are we Now and where should we Go?
    Ryden, Lars
    Mellbin, Linda
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (06) : 690 - 692